Takeaki Satoh

975 total citations
35 papers, 624 citations indexed

About

Takeaki Satoh is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Takeaki Satoh has authored 35 papers receiving a total of 624 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hepatology, 29 papers in Epidemiology and 4 papers in Infectious Diseases. Recurrent topics in Takeaki Satoh's work include Hepatitis C virus research (29 papers), Liver Disease Diagnosis and Treatment (25 papers) and Hepatitis B Virus Studies (20 papers). Takeaki Satoh is often cited by papers focused on Hepatitis C virus research (29 papers), Liver Disease Diagnosis and Treatment (25 papers) and Hepatitis B Virus Studies (20 papers). Takeaki Satoh collaborates with scholars based in Japan and United States. Takeaki Satoh's co-authors include Makoto Nakamuta, Shinji Shimoda, Hideyuki Nomura, Koichi Azuma, Kazuhiro Takahashi, Jun Hayashi, Kazufumi Dohmen, Eiji Kajiwara, Eiichi Ogawa and Norihiro Furusyo and has published in prestigious journals such as Gut, Journal of Hepatology and Life Sciences.

In The Last Decade

Takeaki Satoh

34 papers receiving 607 citations

Peers

Takeaki Satoh

HEPAT

EPIDE

RHEUM

Riina Salupere Estonia

Angie Price United States

Fred Poordad United States

C.-L. Jen Taiwan

Zu-Yau Lin Taiwan

Fernando E. Membreno United States

Wiesław Kryczka Poland

J. Toyota Japan

Emilio Suárez Spain

Christiane Stern France

Riina Salupere Estonia

Takeaki Satoh

593 ×1.1

HEPAT

561 ×1.1

EPIDE

112 ×1.4

51 ×1.0

36 ×0.8

RHEUM

Citations per year, relative to Takeaki Satoh Takeaki Satoh (= 1×) peers Riina Salupere

Countries citing papers authored by Takeaki Satoh

Since Specialization

Citations

This map shows the geographic impact of Takeaki Satoh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takeaki Satoh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takeaki Satoh more than expected).

Fields of papers citing papers by Takeaki Satoh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takeaki Satoh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takeaki Satoh. The network helps show where Takeaki Satoh may publish in the future.

Co-authorship network of co-authors of Takeaki Satoh

This figure shows the co-authorship network connecting the top 25 collaborators of Takeaki Satoh. A scholar is included among the top collaborators of Takeaki Satoh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takeaki Satoh. Takeaki Satoh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ogawa, Eiichi, Motoyuki Kohjima, Toshimasa Koyanagi, et al.. (2025). Five‐Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment. Journal of Gastroenterology and Hepatology. 40(10). 2560–2567.

Ogawa, Eiichi, Hideyuki Nomura, Makoto Nakamuta, et al.. (2020). Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver International. 40(7). 1578–1589. 37 indexed citations

Ogawa, Eiichi, Hideyuki Nomura, Makoto Nakamuta, et al.. (2019). Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysis. Hepatology Research. 50(2). 174–181. 5 indexed citations

Ogawa, Eiichi, Norihiro Furusyo, Koichi Azuma, et al.. (2018). Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease. Antiviral Research. 159. 143–152. 19 indexed citations

Ogawa, Eiichi, Norihiro Furusyo, Hideyuki Nomura, et al.. (2016). Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. Antiviral Research. 136. 37–44. 27 indexed citations

Ogawa, Eiichi, Norihiro Furusyo, Eiji Kajiwara, et al.. (2015). Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non‐cirrhotic patients with chronic hepatitis C virus genotype 1b infection. Journal of Gastroenterology and Hepatology. 30(12). 1759–1767. 8 indexed citations

Ikezaki, Hiroaki, Hideyuki Nomura, Norihiro Furusyo, et al.. (2015). Efficacy of interferon‐beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Hepatology Research. 46(3). E174–80. 3 indexed citations

Ogawa, Eiichi, Norihiro Furusyo, Eiji Kajiwara, et al.. (2015). Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C. Journal of Gastroenterology and Hepatology. 30(8). 1309–1316. 8 indexed citations

Ogawa, Eiichi, Norihiro Furusyo, Kazufumi Dohmen, et al.. (2015). Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. Journal of Viral Hepatitis. 22(12). 992–1001. 4 indexed citations

10.

Ogawa, Eiichi, Norihiro Furusyo, Makoto Nakamuta, et al.. (2014). Efficacy and safety of splenectomy in telaprevir‐based triple therapy for chronic hepatitisCpatients with thrombocytopenia and advanced fibrosis. Journal of Gastroenterology and Hepatology. 29(9). 1728–1735. 3 indexed citations

11.

Ogawa, Eiichi, Norihiro Furusyo, Eiji Kajiwara, et al.. (2014). Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection. Antiviral Research. 104. 102–109. 8 indexed citations

12.

Furusyo, Norihiro, Eiichi Ogawa, Makoto Nakamuta, et al.. (2013). Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. Journal of Hepatology. 59(2). 205–212. 59 indexed citations

13.

Ogawa, Eiichi, Norihiro Furusyo, Kazuhiro Takahashi, et al.. (2012). An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Journal of Infection and Chemotherapy. 18(5). 689–697. 4 indexed citations

14.

Tamada, Yoko, Hiroshi Yatsuhashi, Naohiko Masaki, et al.. (2011). Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B. Gut. 61(5). 765–773. 36 indexed citations

15.

Ogawa, Eiichi, Norihiro Furusyo, Eiji Kajiwara, et al.. (2011). Evaluation of the adverse effect of premature discontinuation of pegylated interferon α‐2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study. Journal of Gastroenterology and Hepatology. 27(7). 1233–1240. 29 indexed citations

16.

Kainuma, Mosaburo, Norihiro Furusyo, Koichi Azuma, et al.. (2011). Pegylated interferon α‐2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase. Hepatology Research. 42(1). 33–41. 3 indexed citations

17.

Watanabe, Jirô, Masami Kuniyoshi, Takeaki Satoh, et al.. (2008). A case of sarcomatoid carcinoma of the liver. Kanzo. 49(8). 376–385. 4 indexed citations

18.

Satoh, Takeaki, et al.. (2007). Hepatocellular Carcinoma Arising from Autoimmune Hepatitis: Report of a Case. Surgery Today. 37(8). 716–718. 6 indexed citations

19.

Satoh, Takeaki & Akihide Masumoto. (2007). Accordion Index: A new tool for the prediction of the efficacy of peg‐interferon‐α‐2b and ribavirin combination therapy for chronic hepatitis C. Hepatology Research. 38(3). 315–318. 4 indexed citations

20.

Satoh, Takeaki, et al.. (1996). The effects of pravastatin, an HMG-CoA reductase inhibitor, on cell viability and dna production of rat hepatocytes. Life Sciences. 59(14). 1103–1108. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact